DiaMedica Therapeutics Inc. (DMAC)
Free
No email, no account, no signup.
Pulling latest news for DiaMedica Therapeutics Inc.…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Clinical-stage biopharmaceutical company
Market Cap
$351M
We're already tracking DiaMedica Therapeutics Inc. — here are the latest events we've registered
Recent News
- On May 6, 2026, DiaMedica reported first quarter 2026 financial results and provided an update on its Phase 2/3 ReMEDy2 trial for acute ischemic stroke. The company confirmed that its current cash position of approximately $51 million is expected to fund operations into the third quarter of 2026. Enrollment continues across clinical sites for both its stroke and preeclampsia programs.
Want to know how this news affects DiaMedica Therapeutics Inc.? Order the analysis.
Order analysis – $4.99
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of DiaMedica Therapeutics Inc. will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.